Thymosin Alpha-1 Peptide For Sale
Buy Thymosin Alpha-1 peptide: 5mg, 10mg or 50mg listed purchase quantities. Compare live prices across 11 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy Thymosin Alpha-1 peptide starting at $31.50/purchase from 11 listed vendors. Compare 5mg, 10mg and 50mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does Thymosin Alpha-1 cost per month?
An illustrative Thymosin Alpha-1 cost model works out to about $46.11 per month: Ascension Peptides's listed 10 mg purchase quantity at $35.50 with code WPA, divided into 1.5 mg amounts 2x weekly. This quantity provides 6.7 nominal portions — about 3.3 weeks at the selected cadence, before preparation losses or stability limits — for roughly $10.65 per week or $46.11 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 356 calculator runs; overall cadence comes from 88 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About Thymosin Alpha-1
FDA-approved (related product)Also known as: Thymalfasin · Zadaxin · TA-1Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide most often sourced for immune-support and antiviral research. Sold abroad as the approved drug Zadaxin for chronic hepatitis B and C, it holds FDA orphan-drug designation but no full U.S. approval. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy Thymosin Alpha-1:
- A third-party COA showing ≥98% purity by HPLC plus mass-spec confirmation of the 28-amino-acid sequence — not just an in-house "lab tested" badge.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill: a labeled 10mg vial should assay close to 10mg. Under-filled vials are a common failure mode that throws off reconstitution math.
Randomized trials and large registry data support efficacy in chronic hepatitis B (Andreone et al.), chronic hepatitis C combination regimens, and post-vaccine immune response in elderly subjects.[3] During the COVID-19 pandemic, several Chinese cohort studies reported reduced mortality in severe COVID-19 patients treated with thymosin alpha-1 as an adjunct — these were observational and not confirmed in randomized Western trials.[4]
Regulatory: Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. FDA orphan-drug designation for hepatitis B, malignant melanoma, and DiGeorge syndrome, but no full FDA approval. Research-grade material is not for human use.
Thymosin Alpha-1: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how Thymosin Alpha-1 works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
Thymosin alpha-1 is a 28-amino-acid N-acetylated polypeptide originally isolated by Allan Goldstein's group from bovine thymus fraction 5 in the early 1970s and later chemically synthesised for therapeutic use as Zadaxin.[1] Despite its name and historical association with the thymus gland, it does not act as a thymic-hormone replacement. Its primary pharmacology is innate-immune signalling through Toll-like receptor 2 and Toll-like receptor 9 on dendritic cells and monocytes, which biases dendritic-cell maturation toward a Th1 pattern, increases IL-2 and interferon-gamma production, and enhances CD8 cytotoxic-T-cell and natural-killer-cell activity.[2] It is administered subcutaneously, typically at 1.6mg twice weekly, and is approved in over 35 countries (Italy, Germany, China, Brazil, and others) for chronic hepatitis B and C; it holds FDA orphan-drug designation for chronic hepatitis B, malignant melanoma, and DiGeorge syndrome but does not have full FDA approval in the United States.[9]
Active research areas
- Chronic hepatitis B (approved indication)Multiple randomised trials including Andreone et al. and the Japan-China Thymosin Study Group reported sustained virological response with thymosin alpha-1, particularly in HBeAg-negative chronic hepatitis B and in combination with interferon-alpha.[3][10] These trials supported approval in more than 35 countries.
- Oncology adjunct (melanoma, hepatocellular carcinoma, NSCLC)Trials and meta-analyses summarised by Garaci et al., King/Tuthill, and re-examined in Costantini et al. report improved disease control and reduced chemotherapy-associated immunosuppression when thymosin alpha-1 is added to standard regimens in malignant melanoma, hepatocellular carcinoma, and non-small-cell lung cancer.[5][6][7] The most consistent benefit appears to be on chemotherapy tolerability rather than direct anti-tumour activity.
- Sepsis and septic shockWu et al. (Intensive Care Med 2013) ran a multicentre Chinese RCT in 361 critically ill septic adults and reported reduced 28-day mortality versus standard care — the strongest single-trial signal for thymosin alpha-1 outside infectious-disease hepatology.[8] FDA orphan designation for severe sepsis was awarded on the back of this and related work, but no Phase 3 trial has confirmed the signal in a Western population.
- COVID-19 (observational only)Chinese cohort studies including Liu et al. reported reduced mortality in severe COVID-19 patients given adjunctive thymosin alpha-1 and partial reversal of lymphocytopenia and T-cell exhaustion.[4] These studies were observational, were not replicated in randomised Western trials, and the molecule did not enter major COVID-19 treatment guidelines.
- Vaccine adjuvant in immunocompromised and elderly populationsCamerini and Garaci review work using thymosin alpha-1 to boost vaccine responses to influenza and hepatitis B in haemodialysis patients and the elderly, with reported improvements in seroconversion rates versus vaccine alone.[11]
Open questions & leading hypotheses (3)
- Hypothesis: Thymosin alpha-1 provides a clinically meaningful immune benefit in chronic non-infectious indications (post-viral fatigue, autoimmune flares, "immune resilience") at the doses used in self-administered protocols.Evidence: The TLR-2/TLR-9 signalling and Th1-bias mechanism is well-characterised in dendritic cell models,[2] and approved-indication evidence shows the molecule modulates real immune endpoints in chronic hepatitis B.[3][10] Counter-evidence: no controlled human trials have been published in post-viral fatigue syndromes, long COVID, or generalised "immune support"; the entire signal in those areas is observational or anecdotal.
- Hypothesis: Adding thymosin alpha-1 to immune-checkpoint-inhibitor therapy improves response rates without increasing immune-related adverse events.Evidence: Costantini et al. summarise pre-clinical and small-trial data suggesting thymosin alpha-1 could synergise with anti-PD-1 therapy by enhancing dendritic-cell antigen presentation.[7] Counter-evidence: no large randomised trial has tested this combination in a contemporary checkpoint-inhibitor regimen, and the immune-bias effect could in principle either help (more T-cell priming) or hurt (more immune-related toxicity) — the empirical answer is not yet in.
- Hypothesis: The Chinese sepsis signal (Wu et al., 2013) will replicate in a Western Phase 3 trial.Evidence: Wu et al. is a properly randomised, multi-centre trial with a pre-specified mortality endpoint and a positive result;[8] the mechanism is biologically plausible in immunosuppressed sepsis. Counter-evidence: the Chinese trial used a different standard-of-care backbone than current Western sepsis bundles, and the broader sepsis-immunotherapy field has a history of single-trial positive signals that do not replicate (e.g., activated protein C / Xigris); a confirmatory Phase 3 in a Western ICU population has not been published.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/LongHaulers, users running self-administered subcutaneous thymosin alpha-1 protocols most often describe gradual subjective improvements in energy, recurrent-infection frequency, and post-exertional malaise over 4–12 weeks at 1.5–4.5mg per week — typical of an immune-modulator rather than a stimulant. Side-effect reports are uncommon and centre on injection-site soreness and a transient flu-like response in the first week.[12][13] A recurring theme is users in post-viral fatigue syndromes (long COVID, post-EBV) cycling Thymosin Alpha-1 for 8–12 weeks at a time and reporting partial recovery; an opposite cohort reports no perceived effect at any dose. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what self-experimenters notice but do not establish that thymosin alpha-1 is safe or effective for any post-viral or chronic-fatigue indication; the only properly controlled evidence is in chronic hepatitis B, selected oncology adjunct settings, and the single Chinese sepsis trial.
Sources & references (13)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Goldstein AL et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA 1972;69:1800–1803. · PMID: 4504377 link
- [2]Romani L et al. Thymosin α1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood 2004;103:4232–4239. · PMID: 14982877 link
- [3]Andreone P et al. A randomized controlled trial of thymosin-α1 versus interferon alpha treatment in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 1996;24:774–777. · PMID: 8855175 link
- [4]Liu Y et al. Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis 2020;71:2150–2157. · PMID: 32442287 link
- [5]Garaci E, Pica F, Sinibaldi-Vallebona P et al. Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 2003;3:1145–1150. · PMID: 12860171 link
- [6]King R, Tuthill C. An overview of the use of thymosin alpha 1 in the treatment of cancer. Ann N Y Acad Sci 2007;1112:367–377. · PMID: 17600293 link
- [7]Costantini C, Bellet MM, Pariano M et al. A reappraisal of thymosin α1 in cancer therapy. Front Oncol 2019;9:873. link
- [8]Wu M et al. Thymosin α1 therapy in critically ill patients with sepsis: a multicenter, double-blind, randomized, controlled trial. Intensive Care Med 2013;39:1117–1127. · PMID: 23552923 link
- [9]FDA Orphan Drug Designations and Approvals — Thymalfasin search results (chronic hepatitis B, malignant melanoma, DiGeorge syndrome). link
- [10]Iino S et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial of the Japan-China Thymosin Study Group. J Viral Hepat 2005;12:300–306. · PMID: 15850471 link
- [11]Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opin Biol Ther 2015;15 Suppl 1:S117–S127. · PMID: 26098768 link
- [12]Community report — r/Peptides Thymosin Alpha-1 protocol and post-COVID recovery discussions (subreddit), accessed May 2026. link
- [13]Community report — r/LongHaulers Thymosin Alpha-1 experience threads in chronic post-viral fatigue (subreddit), accessed May 2026. link
What Thymosin Alpha-1 Costs Right Now
WPA currently tracks Thymosin Alpha-1 from 11 distinct vendors across 13 separate Thymosin Alpha-1 listings. In-stock Thymosin Alpha-1 vials run from $31.50 to $575.91 — a 18.3x spread for the same compound. Ameano Peptides holds the lowest sticker price at $31.50. Normalized to milligrams, Thymosin Alpha-1 costs $3.55/mg to $11.52/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.
Thymosin Alpha-1 is stocked in 3 sizes: 10 mg listed quantity; vial count not recorded; 50 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the Thymosin Alpha-1 listings WPA tracks are: Ascension Peptides — 10mg at $35.50 ($3.55/mg), COA purity 99.39%; Southern Aminos — 10mg at $50.15 ($5.01/mg), COA purity 99.90%; EZ Peptides — 10mg at $52.20 ($5.22/mg), COA purity 99.65%; LA Peptides — 10mg at $53.99 ($5.40/mg), COA purity 99.80%; Flawless Compounds — 10mg at $55.25 ($5.53/mg), COA purity 99.90%.
Thymosin Alpha-1 COA Coverage Across Tracked Vendors
11 of the 13 tracked Thymosin Alpha-1 listings (85%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 11 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 98.60% to 99.90%. 9 listings record more Thymosin Alpha-1 in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 9/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Thymosin Alpha-1 offer. WPA's listing fields do not establish that a report was independently verified.
Thymosin Alpha-1 Calculator Input Observations
In lifetime Thymosin Alpha-1 calculator inputs, 1.5mg is the most frequent entered amount (87 of 356 runs). Separately, 2x/week is the most frequent overall cadence (32 of 88 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1.5mg, 2x/week is most frequent (19 of 40 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 50 mg of listed product divided by 1.5 mg gives roughly 33 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
Thymosin Alpha-1 Discount Codes
13 of the 13 tracked Thymosin Alpha-1 listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About Thymosin Alpha-1
Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide most often sourced for immune-support and antiviral research. Sold abroad as the approved drug Zadaxin for chronic hepatitis B and C, it holds FDA orphan-drug designation but no full U.S. approval.
Thymosin Alpha-1 is tracked under the Recovery Peptides category on WPA. Its reported half-life is ~2 hours. Calculator inputs do not establish why a cadence was selected or validate a protocol. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C.
How to Read the Thymosin Alpha-1 Comparison
- Price per milligram — Every Thymosin Alpha-1 listing is normalized to $3.55/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 11 Thymosin Alpha-1 listings are marked for COA availability, and 11 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The Thymosin Alpha-1 comparison includes 5mg, 10mg, and 50mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each Thymosin Alpha-1 listing, refreshed on a recurring basis.
Frequently Asked Questions: Thymosin Alpha-1
Is it legal and safe to buy Thymosin Alpha-1 for research?
In the US, Thymosin Alpha-1 is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is a synthetic immune-signaling peptide with no approved human form in the US, sold strictly for laboratory research. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 13 Thymosin Alpha-1 listings from 11 vendors.
How do I verify a Thymosin Alpha-1 COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific Thymosin Alpha-1 batch. Check that the report identifies the compound (actually thymosin alpha-1, not thymosin beta-4 (TB-500) or an underdosed vial), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Thymosin Alpha-1 specifically, 11 of 13 tracked listings (85%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 11 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 9/26.
Which Thymosin Alpha-1 vendor should I pick?
There's no single "best" Thymosin Alpha-1 vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Thymosin alpha-1 is easy to confuse with thymosin beta-4, so favor vendors whose COA names the exact alpha-1 sequence. 11 vendors currently carry Thymosin Alpha-1, and Ascension Peptides holds the best true value at $3.55/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does Thymosin Alpha-1 cost — and how do I know I'm not overpaying?
Judge Thymosin Alpha-1 by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in 10 mg vials, so compare $/mg across those rather than the sticker price on one vial. Tracked Thymosin Alpha-1 listings currently run $3.55/mg to $11.52/mg across 5mg, 10mg, 50mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much Thymosin Alpha-1 do I need for one full cycle?
In lifetime Thymosin Alpha-1 calculator inputs, 1.5mg is the most frequent entered amount (87 of 356 runs). Separately, 2x/week is the most frequent overall cadence (32 of 88 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1.5mg, 2x/week is most frequent (19 of 40 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 50 mg purchase quantity by 1.5 mg gives roughly 33 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for Thymosin Alpha-1?
Participating Thymosin Alpha-1 vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 13 of the 13 tracked Thymosin Alpha-1 listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare Thymosin Alpha-1 prices and listing details?
This comparison shows 13 tracked listings for Thymosin Alpha-1 in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.